- Home
- NEO
NEO
NeoGenomics Inc.
as 12-20-2024 3:40pm EST
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | FORT MYERS |
| Market Cap: | 2.3B | IPO Year: | 1999 |
| Target Price: | $20.30 | AVG Volume (30 days): | 756.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.77 - $21.22 | Next Earning Date: | 02-18-2025 |
| Revenue: | $644,118,000 | Revenue Growth: | 12.06% |
| Revenue Growth (this year): | 12.98% | Revenue Growth (next year): | 9.83% |
Stock Insider Trading Activity of NeoGenomics Inc. (NEO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Olivo Alicia C | NEO | General Counsel | Nov 15 '24 | Sell | $15.36 | 5,175 | $79,475.06 | 37,129 |
Latest NeoGenomics Inc. News
NEO Breaking Stock News: Dive into NEO Ticker-Specific Updates for Smart Investing
Argus Research
4 days ago
NEO: Rating increased to a HOLD
MT Newswires
5 days ago
Natera Expands Lawsuit Against NeoGenomics to Include Additional Patent
Business Wire
11 days ago
NeoGenomics’ Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma
Argus Research
11 days ago
NEO: Raising target price to $17.00
MT Newswires
12 days ago
Jefferies Initiates NeoGenomics at Buy With $22 Price Target
Business Wire
13 days ago
NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting
Argus Research
18 days ago
NEO: Raising target price to $16.00
Business Wire
a month ago
NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
Compare NEO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NEO NeoGenomics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.